← Back to headlines
Acadia Reaffirms 2026 Revenue Guidance Ahead of Remlifanserin Phase II Readout
Acadia Pharmaceuticals has reaffirmed its 2026 total revenue guidance of $1.22 billion to $1.28 billion as the readout for its remlifanserin Phase II ADP trial approaches.
7 May, 08:42 — 7 May, 08:42
Sources
Showing 1 of 1 sources
